Healthcare Innovation Related Content
Scientists found racial differences in COVID care home deaths
According to new data, COVID care home deaths in the United States are influenced by race - with majority non-White care homes experiencing 3.3 times more deaths.
Upskilling knowledge and training of diabetes management
A new medical education programme for diabetes healthcare providers in the UK is focusing on upskilling the knowledge and training of diabetes management technologies & devices.
Epilepsy research: Improving infrastructure & management
Arun Swaminathan MD, Assistant Professor of Neurology and Epilepsy at the University of Nebraska Medical Center, considers the importance of improving infrastructure and management of epilepsy research.
Bharat Biotech COVID vaccine shows 81% efficacy at Phase Three
The Bharat Biotech COVID vaccine, COVAXIN, appears to be 81% efficient against the virus in Phase Three of clinical trials.
The AstraZeneca vaccine is atleast 60% effective for people aged 70 and over
A study examining older people in the UK found that only one dose of the AstraZeneca vaccine is atleast 60% effective for people aged 70 and over.
Scientists find that elevated neutrophils can predict severe COVID and death
Researchers at Yale believe that blood tests could predict severe or critical COVID cases, because blood holds a series of interesting biological signals about a person.
FDA approves the Johnson & Johnson vaccine for use
The US Food and Drug Administration (FDA) approved the Johnson & Johnson vaccine, with an efficacy of 86%, as the next to be rolled out across the US.
The Brazilian COVID mutation has been found in the UK
The UK has found six confirmed cases of the Brazilian COVID mutation yesterday (28 February) - but an individual who tested positive three weeks ago is still being traced throughout the country.
The window for convalescent plasma donation is just under two months
New data suggests that before 60 days of COVID symptoms beginning is the best window for convalescent plasma donation - which is how antibodies were created in countless COVID-19 patients before vaccines.
What are the priority groups for phase two of UK vaccinations?
The Government unveiled the confirmed priority groups for phase two of UK vaccinations - the Joint Committee on Vaccination and Immunisation (JCVI) is choosing age as the deciding factor.
1.17 million doses of the AstraZeneca vaccine could expire in Germany
Germans have only taken 270,986 AstraZeneca doses so far, leaving roughly 1.17 million doses in storage across the country - but these shots are due to expire in less than six months.
COVID-19 and diabetes telehealth
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechCasting Group, explains how the COVID-19 pandemic is the scenario for testing and demonstrating the successful implementation of diabetes telehealth platforms.
FDA reveals that Johnson & Johnson vaccine is 86% effective
New documents from the FDA show that the Johnson & Johnson vaccine appears to be 86% effective against COVID-19 - signalling that it will soon be approved in the US.
Targeted policy support for emerging biomedical innovations
Michael Morrison, Senior Researcher in Social Science at the University of Oxford, illustrates the importance of emerging biomedical innovations in the UK.
Scientists use machine learning to identify likelihood of severe COVID
The research team believe that some people have a genetic predisposition that increases likelihood of severe COVID, which may be crucial to understanding how mutations could change outcomes.
A national strategy for social care could save the NHS £1 billion every year
Research found that the supported housing and integrated mental health system could save the NHS £950 million if used as a national strategy for social care.
Science needs to overcome “structural racism” to end the HIV epidemic
A new report published in The Lancet investigates why 43% of HIV deaths in 2018 happened in the Black community, with policy solutions for the ongoing HIV epidemic.
Hong Kong approves the Sinovac COVID vaccine for use
The Sinovac COVID vaccine was revealed to be working at 50.4% efficacy by the Butantan Institute last month, but new data suggests that this could actually be 62%.
The spike mutation makes COVID eight times more infectious
The spike protein mutation found in the Brazilian, South African and UK variants of COVID-19 can make the virus eight times more infectious.
Can an mRNA vaccine be used to cure some types of cancer?
COVID brought the idea of mRNA vaccines to the attention of the world - now, cancer researchers are investigating how a similar vaccine could stop tumours in a single treatment.